DEC 03, 2018 11:47 PM PST

Genes Involved In Dementia Identified

Dementia results in decline of the memory and other cognitive functions. While Alzheimer’s accounts for up to 80 percent of dementia cases, there are other causes as well, including vascular dementia post-stroke, thyroid and vitamin deficiencies. Things sure do start small with dementia but eventually result in drastic changes in the quality of life.

Advances in high-throughput whole genome sequencing had led to a dynamic shift in understanding the genetics associated with neurodegenerative diseases. Genetic factors have been recognized as a critical contributor for dementia and identifying these genes will eventually allow for gene-specific therapeutics to be developed. Although scientists have identified genes associated with dementia risk, there is little understanding of how those genes contribute to the cascade of events that lead brain cells to die.

The research team sought to solve that puzzle through an approach known as "systems biology," which applies powerful genomic and analytic tools to studying the genome holistically, taking into account the complex interactions of the thousands of genes and the cells and proteins they produce.

A UCLA-led research team has identified genetic processes involved in the neurodegeneration that occurs in dementia—an essential step on the path toward developing therapies that could slow or halt the course of the disease.  The findings appear on December 3rd in the journal Nature Medicine.

The researchers discovered two significant groups of genes involved in mutations that result in an overproduction of a protein called tau, a hallmark of the progressive loss of neurons seen in significant forms of dementia. The study was primarily done in mouse models of dementia, although the researchers performed additional experiments that indicated the same genetic process occurs in human brains.

Brain scan of dementia patient shows neurons with Tau protein (in green) and reactive astrocyte cells (in red). Credit: UCLA/Geschwind lab

Armed with that knowledge, the team searched an extensive database of the genetic effects of experimental drugs to identify those that might alter this loss of neurons or neurodegeneration. In human cell cultures, the researchers showed that the use of these molecules interfered with neurodegeneration.

"Our study is the most comprehensive published effort to date to identify the source of neurodegeneration across species and provides an important roadmap for the development of potentially effective new drugs for Alzheimer's disease and other dementia," said senior author Dr. Daniel Geschwind, a professor of neurology and psychiatry who holds the Gordon and Virginia MacDonald Distinguished Chair in Human Genetics at the David Geffen School of Medicine at UCLA.

The researchers used systems biology to identify genetic processes in a mutation that results in the overproduction of tau in frontotemporal dementia, a form of early-onset dementia. A similar process also has been shown to play an essential role in Alzheimer's disease and another type of dementia known as supranuclear palsy, which affects both movement and cognition.

Geschwind's team hypothesized that a reason why research with mouse models of dementia often fails to produce results translatable to humans is that most mouse studies have relied on a single inbred strain.

To increase the likelihood that their findings would have broader implications, the researchers studied the mutation caused by frontotemporal dementia in three genetically distinct strains of mice. The team looked at the genetic activity occurring in different parts of and points of time in a degenerating brain.

In the study, two gene clusters were found to be associated with neurodegeneration across all three mouse models and in the susceptible regions of the brain.

"There is still a significant amount of work that needs to be done to develop drugs that could be effectively used in humans against these targets, but this is an encouraging step," said Geschwind, who also serves as co-director of the Center for Neurobehavioral Genetics at the Semel Institute for Neuroscience and Human Behavior at UCLA, and senior associate dean and associate vice chancellor of precision medicine at UCLA Health.

Sources: Nature Medicine, The University of California- Los Angeles

About the Author
  • Aswini Kanneganti is an experienced research scientist from Dallas, Texas. Her interests include neuroscience, medical devices, and neuromodulation.
You May Also Like
SEP 21, 2019
Cell & Molecular Biology
SEP 21, 2019
Why Sleep is Good for Us
Animals spend a lot of their lifetime asleep, and scientists have sought to understand the physiological purpose of all that spent time....
SEP 21, 2019
Technology
SEP 21, 2019
Artificial Intelligence May Soon Detect Brain Aneurysms
Artificial intelligence (AI) may soon help doctors diagnose brain aneurysms which are bulges in blood vessels that can lead to stroke, brain damage, and de...
SEP 21, 2019
Genetics & Genomics
SEP 21, 2019
How Wolves Evolved into Dogs
Wolves and dogs share 99.9% of their DNA. Technically still the same species, they can also produce healthy offspring. But having said that, there’s ...
SEP 21, 2019
Drug Discovery & Development
SEP 21, 2019
What does MDMA Therapy Look Like?
The Multidisciplinary Association for Psychedelic Studies (MAPS) aims to create an FDA-approved standardized MDMA-assisted psychotherapy practice for PTSD ...
SEP 21, 2019
Immunology
SEP 21, 2019
Making Opioids Safer
The opioid crisis results in 130 American deaths every day, and both prescribed and synthetic opioids are at the core of the epidemic.  Any other drug...
SEP 21, 2019
Plants & Animals
SEP 21, 2019
Crows Can Be Silent If They Choose to Be
Researchers have long thought that songbirds unleash their colorful vocalizations involuntarily in response to activities happening around them, such as fo...
Loading Comments...